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Introduction
For many malignancies, serum tumour markers play
an important role in patient management. In breast can-
cer the role of serum markers is less well established [1-
3]. The elevation of serum markers in breast cancer may
be helpful in early diagnosis, determining prognosis,
predicting response or resistance to specific therapies,
surveillance after primary surgery, and monitoring thera-
py in patients with advanced disease [4-6]. Breast cancer
is a heterogenic disease and none of the available mark-
ers is increased in all patients with breast cancer even in
an advanced stage of the disease [2,4]. It is not known
whether the presence of increased preoperative level of
the most widely used markers as CA 15-3 and CEA
depends on the histological type of the breast cancer.
The aim of the study was to assess the relationship
between histological type of the breast cancer and the
presence of the increased serum levels of breast cancer
markers like CEA and/or CA 15-3.
Material and methods
Tumour samples. A total of 428 patients were treated at The
Department of Surgery of Wroclaw Medical University from 2005
to 2008 due to the diagnosis of breast cancer. All of them had their
preoperative CA 15-3 and CEA serum concentrations measured. In
all patients tumours were invasive cancers in stages I-III, and the
mean age of patients was 52.5 years (range  24-83 years). All the
patients in the study were women and 54.5% of them were post-
menopausal.
Tumour markers. Studied tumour markers levels were measured
by immunoassays: Enzymum test 300 using the cutoff value of 5
ng/ml for CEA and Enzymum-test CA 15-3 using the cutoff value
of 40 units/ml for CA 15.3. Intra- and interassay variations for
both markers were 5% and 10%, respectively. Measurements of
serum concentrations of CEA and CA 15-3 were blinded. In all
cases histological slides from paraffin wax embedded material
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 48, No. 1, 2010
pp. 26-29
The importance of preoperative elevated serum levels 
of CEA and CA15-3 in patients with breast cancer
in predicting its histological type
A. K. Agrawal1, M. Jelen3,  J. Rudnicki1, Z. Grzebieniak1, D.  Zyœko4, W. Kielan1, 
J. S³onina2,  G. Marek1
12nd Department of General and Oncological Surgery, Wroclaw Medical University, Wroclaw, Poland
2Department of Radiology, Wroclaw Medical University, Wroclaw, Poland
3Department of Pathology, Wroclaw Medical University, Wroclaw, Poland
4Teaching Department for Emergency Medical Services, Wroclaw Medical University, Wroclaw, Poland
Abstract: It is not known whether in patients with breast cancer the occurrence of elevated serum tumour markers depends
on its histological type. The aim of the study was to assess relationship between breast cancer histological type and the pres-
ence of increased serum levels of CEA and CA 15-3. The study population was 428 patients (all women, mean age 52.5
years), treated at The Department of Surgery of Wroclaw Medical University from 2005 to 2008 due to breast cancer. All
of them had their preoperative CA 15-3 and CEA serum concentrations measured. According to the TNM system, 21% of
patients were in stage I, 32.5% in stage II, 46.5% in stage III of the disease. In patients with ductal type of the cancer the
elevated serum levels of CEA and CA 15-3 were observed in 48.7% and 42.2%, in lobular type in 42.4% and 52.5%, and in
non-ductal/tubular types in 48.1% and 40.4% (p=N/S). Stepwise logistic regression analyses showed that ductal breast can-
cer is related to elevated CEA and normal CA 15-3 serum levels. The histological types of breast cancer are not significantly
related to elevated serum levels of CEA and/or CA 15-3. 
Key words: breast cancer, serum tumour marker, CA 15-3, CEA, histological type
Correspondence: A.K. Agrawal, 2nd Department of General and
Oncological Surgery, Wroclaw Medical University, Borowska
Str. 213, 50-556 Wroclaw, Poland; tel.: (+48) 609289027, 
fax.: (+4871) 7828834, e-mail: dranilpreeti@gmail.com 
were critically reviewed and classified according to the criteria of
WHO [7]. 
Statistical analysis. The frequency of occurrence of the elevated
serum levels of CEA and CA 15-3 tumour markers were calculat-
ed for the whole population and for the groups according to the dis-
ease stage assessed according to the TNM system and histological
types of the carcinomas. The differences between these frequencies
were compared using Ch2 test. Taking into account that ductal can-
cer malignancy was the most common type, the patients were
dichotomized according to its presence or absence. The logistic
regression analysis was performed to assess the relationship
between ductal type of breast cancer and the presence of the CEA
and CA 15-3 elevation in the serum of these patients and the stage
of the disease. P less than 0.05 was regarded as significant.
Results
According to staging criteria of the TNM system, 21%
of patients (90 cases) were in stage I, 32.5% (139
cases) in stage II, 46.5% (199 cases) in stage III. 
At the time of surgery none of the patients present-
ed distant metastases. Histopathological types of
breast cancers included ductal carcinoma 64.7% (277
cases), lobular carcinoma 23.1% (99 cases), and other
types 12.1% (52 cases).
The CA 15-3 and CEA serum levels were available
in records of the all patients in the study and CA 15-3
levels were in the normal range in 55.6% and elevated
in 44.4%, CEA levels were in the normal range in
52.8% and elevated in 47.2% (p=NS).
Elevated CA15-3 levels were observed in 38.9% of
stage I patients, 42.4% of stage II, and 46.2% of stage
III patients (p=NS).
Elevated serum levels of CEA were observed in
47.8% of stage I patients, 48.2% of stage II and 46.2%
of stage III patients (p=NS).
In patients with ductal carcinoma, elevated serum
levels of CEA and CA13-5 were observed in 48.7%
and 42.2% respectively. In the lobular type, the respec-
tive figures were 42.4% and 52.5%, and in non-duc-
tal/tubular types were 48.1% and 40.4% (p=N/S). Sta-
tistical analysis revealed a trend toward higher fre-
quency of elevated CEA in patients with ductal carci-
noma vs lobular type.
The presence of serum CEA and CA15-3 elevation
in the patients with breast cancer divided into groups
with respect to the stage of the disease was presented
in Table 1. The occurrence of CEA and CA15-3 eleva-
tion in the patients with breast cancer divided into
groups with respect to the histological type was shown
in Table 2. The presence of serum CEA and CA15-3
elevation in the patients with breast cancer divided into
group with ductal and non-ductal type of cancer is
depicted in Table 3.
Logistic regression analysis revealed that ductal
type of breast cancer was related to the elevated serum
level of CEA (OR: 6.2 95% CI (2.1-18.4) p<0,001).
The elevated serum level of CA 15-3 was negatively
related to the occurrence of ductal cancer (OR: 0.16,
95% CI (0.05-0.46) p<0.001) and the stage of the dis-
ease was not related to the ductal type.
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Table 1. The occurrence of CEA and CA15-3 elevation in the
patients with breast cancer divided into groups according to the
stage of the disease.
Table 2. The occurrence of CEA and CA15-3 elevation in the
patients with breast cancer divided into groups according to the
histological type.
Table 3. The presence of CEA and CA15-3 elevation in the
patients with breast cancer divided into group with ductal and non-
ductal cancer group. The percentage of patients refers to the group
according to histological type.
Discussion
CEA and CA 15-3 are the most widely used serum
markers in breast cancer. The occurrence of elevated
levels of these tumour markers are similar to those
observed in other studies and confirm their low sensi-
tivity for early breast cancer [8].
The main finding of our study was lack of relation-
ship between the elevation of the serum level of breast
cancer tumour markers CEA and CA 15-3 and the can-
cer  histological type. The logistic regression analysis
allowed to show that the presence of ductal type of
breast cancer was related with the normal serum level
of CA 15-3 and elevated serum level of CEA. Indeed,
normal levels of CA 15-3 and elevated levels of CEA
were present in 6.5% of patients with ductal type and
only in 2.6% of patients with non-ductal type thus the
ratio of the patients fulfilling this criterion in the for-
mer group is nearly 3 times higher than in the later,
however low absolute numbers of these patients
reduced the clinical importance of this finding. Our
results are concordant with the results of other authors
who have shown that serum CEA was present in each
histological type of the breast tumours and in the inva-
sive ductal tumors it was slightly higher than in the
lobular ones [9]. Different histological types of breast
cancer have similar propensity to produce increased
amount of serum CEA and CA 15-3 although the
immunohistochemical tests revealed that in ductal
tumors more cancer cells stain for CEA than in other
breast cancers [10]. Oncogenic mechanisms may be
heterogenic in breast ductal and lobular epithelium but
these two origins of breast cancer are not considerably
different with respect to the increased serum level of
CEA and CA 15-3. 
The second finding was the lack of significant
dependence of the disease stage and the occurrence of
elevated levels of CEA and CA 15-3. The results of
other authors regarding the relationship between dis-
eases stage and the level of tumour markers are dis-
cordant. Some authors have reported more frequent
occurrence of the elevated plasma levels of these
tumour markers in more advance stages of that disease
but others have reported lack of statistical relation
between serum levels of these markers with disease
stage [11]. Moreover the preoperative serum CA 15-3
level is useless for determining the histologic grade of
the tumor [3]. The differences between studies may
depend on the clinical characteristics of the studied
group. The relation between disease stage and the pres-
ence of the elevation of CEA and CA 15-3 levels is
more obvious in studies performed on the unselected
patients with breast cancer with the subgroup of
patients with metastases. Our group was preselected as
only the surgical patients were included. 
CA 15-3 is used for surveillance and monitoring of
therapy in patients with breast cancer, however even in
advanced stage disease its levels may remain within
normal range [12,13]. In these circumstances it is rec-
ommended to consider testing other tumour markers
for the monitoring purposes. Our results indicate low
significance of the CEA serum level for this purpose as
only about 10% of patients with normal level of CA
15-3 had elevated CEA serum concentration. Similar
results for both markers (either both negative or both
positive) was observed in 92% of cases whereas only
in 8% of the patients one of the studied markers is ele-
vated whereas the second was within normal values.
That indicated low efficacy of the method of tumour
marker analysis relying on measurement of CEA
serum level when CA 15-3 is within normal range.
Other authors have also reported that analysis of CEA
serum level along with that of CA 15.3, rather than the
latter alone added only a 6% to its sensitivity in over-
all population [14]. The histological types of breast
cancer are not significantly related with the presence
of the elevated serum levels of CEA and /or CA 15-3.
The elevated level of CEA and normal level of CA 15-
3 significantly indicate ductal cancer although this
configuration of tumor marker levels is not common.
In the studied population most of patients had concor-
dant (either elevated or both normal) levels of CEA
and CA 15-3 thus the examination of CEA when CA
15-3 is within normal values yields only a small
increase in sensitivity. The presence of elevated serum
levels of CEA and CA 15-3 was not significantly relat-
ed with the stage of the disease according to TNM
classification in the group of breast cancer patients
referred for breast surgery.
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